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A heritable immunological disease
First described in 1932, CD is an in-
flammatory  disease  of  the  digestive 
tract that affects 0.1–0.2% of the adult 
population. Despite decades of investi-
gation, the pathogenesis of CD has re-
mained elusive (Baumgart and Carding, 
2007).  The  inflammation  associated 
with  CD  can  occur  anywhere  along 
the route from the mouth to the anus. 
Although clinically defined as a diges-
tive  condition,  there  is  no  evidence 
that CD involves defects in epithelial 
or other digestive cells.
In essence, CD is an immunological 
disease in the hematopoietic sense of 
the term. This classification had long 
been suggested by the tissue lesions as-
sociated with CD, which consist pri-
marily of granulomas, and by the fact 
that patients often respond to immuno-
suppressive therapy. Perhaps the best 
proof of an immunological etiology is 
the observation that CD was cured in 
several patients who received allogeneic 
hematopoietic stem cell transplantation 
(HSCT). Likewise, some individuals ac-
quired CD after receiving HSCT from 
donors with CD. Although CD is im-
mune mediated, it is not an autoimmune 
disease, as the immunological process 
appears to be triggered by the content of 
the gut lumen rather than a self-antigen.
CD is also a genetic disease, as sug-
gested  by  the  higher  concordance  in 
monozygotic versus dizygotic twins, the 
higher risk of disease in first-degree rela-
tives of probands, and the high rate of 
family history among patients. However, 
CD does not follow a uniform mode of 
inheritance, a finding that has been 
conservatively interpreted to suggest a 
polygenic predisposition at both the in-
dividual and population levels (Baumgart 
and Carding, 2007; Van Limbergen 
et al., 2009). To date, CD is widely 
accepted as a genetically determined im-
munological disease that manifests prin-
cipally in the gut and is triggered by 
bowel contents. But this is as far as scien-
tific consensus and certainty go.
Progress and pitfalls of CD research
The  immunological  basis  of  CD  has 
been studied primarily in various mouse 
models of colitis. Most of these models 
have suggested that colitis, and by in-
ference CD, are mediated by T lym-
phocytes (Ostanin et al., 2009). In the 
late 1990s, human genome-wide link-
age  (GWL)  studies  were  performed, 
followed by genome-wide association 
(GWA) studies in the late 2000s. Inter-
estingly, the locus with the most robust 
association with CD and the first gene 
identified  by  GWL  studies,  NOD2/
CARD15, was expressed in the myeloid 
rather than the lymphoid lineage (Hugot 
et al., 2001; Ogura et al., 2001).
NOD2 is a cytosolic receptor that 
recognizes bacterial peptidoglycans, par-
ticularly mycobacterial N-glycolyl mu-
ramyl dipeptide (Coulombe et al., 2009). 
After the identification of NOD2 as a 
CD-associated gene, various immuno-
logical scenarios were imagined. Some 
studies claimed that the CD-predis-
posing  NOD2  mutant  alleles  were 
hypomorphic, others that they were hy-
permorphic. Most, however, attributed 
CD pathogenesis to NOD2-mediated 
recognition  of  bacterial  peptidogly-
can and subsequent activation of the   
NF-B pathway. The observation that 
other alleles of NOD2 caused a clearly 
distinct, remotely related, and highly 
penetrant Mendelian autosomal dom-
inant  systemic  disorder  called  Blau 
syndrome was left unexplained (Miceli-
Richard et al., 2001).
Only  recently  did  a  superb  study 
reveal the surprising fact that CD-predis-
posing NOD2 mutant proteins, unlike 
their  wild-type  counterparts,  actively 
and specifically suppress the transcrip-
tion of IL-10 in a peptidoglycan- and 
NF-B–independent manner (Noguchi 
et  al.,  2009).  This  phenomenon  was 
restricted to human NOD2 and IL-10 
and was not found in their mouse or-
thologues, a distinction that highlights 
the necessity of human immunological 
studies (Casanova and Abel, 2004; Davis, 
2008; Hayday and Peakman, 2008). 
Other loci were identified by GWL 
studies, but the impact of these loci on 
disease was lower and, like NOD2, they 
were not universal CD susceptibility 
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impaired bacterial clearance was evident 
for high, but not low, bacterial doses. 
Overall,  these  experiments  suggest  a 
causal link between impaired inflamma-
tion  and  impaired  bacterial  clearance. 
The intestine was not wounded with 
bacteria, but the skin defect was pro-
posed to be systemic and to involve the 
gut in particular. In fact, E. coli was 
chosen for these studies because of its 
abundance in the intestinal flora. It is 
important  to  reiterate  that  the  defect 
was seen only with high bacterial loads, 
given that the highest bacterial load in 
the human body is found in the intesti-
nal tract, which is the primary target of 
CD. Impaired bacterial clearance pre-
sumably results in chronic inflammatory 
responses, accompanied by accumula-
tion of granulomas consisting of macro-
phages and T lymphocytes. Therefore, 
in this model, excessive inflammation is 
the consequence of an underlying im-
munodeficiency rather than the primary 
cause of CD pathogenesis (Fig. 1).
Tracking the culprit
That impaired inflammation hampers 
bacterial clearance is understandable, but 
what causes the impaired attraction of 
granulocytes to experimental wounds, 
and  by  extension,  to  natural  mucosal 
breaches, in CD patients? The patients’ 
granulocytes appear to be intrinsically in-
tact, as they responded normally to in vi-
tro exposure to known chemoattractants. 
However, macrophages derived from 
blood monocytes of CD patients failed to 
secrete proinflammatory cytokines and 
chemokines, including some that attract 
granulocytes  (Smith  et  al.,  2009).  Re-
markably, like the impaired attraction of 
granulocytes and bacterial clearance, this 
phenotype was shared by all CD patients 
tested, regardless of the NOD2 genotype 
in particular, and was markedly distinct 
from healthy controls. The defect applied 
to  various  experimental  conditions,  in-
cluding macrophages stimulated by E. coli 
or microbial products.
The  mechanism  underlying  the 
cytokine defect was not impaired tran-
scription  of  the  corresponding  genes, 
nor was it impaired translation of the 
corresponding mRNAs. Instead, the cyto-
kines appeared to be destroyed inside 
derstandable  causal  relationship  at  the 
cellular, individual, and population lev-
els? Missing intelligibility strongly sug-
gests that the phenomenon has not been 
correctly understood. And if the immuno-
logical basis of CD is scientifically intel-
ligible,  one  can  also  hope  that  this 
knowledge would be helpful to patients. 
This is unlikely to be the case if CD is 
the result of a myriad of genetic poly-
morphisms in various genes involved in 
multiple  pathways,  each  conferring  a 
very modest relative risk. What is more 
likely  is  that  missing  heritability  and 
missing intelligibility are two sides of 
the same coin that account for the poor 
clinical impact of past investigations.
Deficit drives excess inflammation
The first breakthrough toward an un-
derstanding of the pathogenesis of CD 
came  in  1976  when  Anthony  Segal 
demonstrated impaired influx of granu-
locytes into skin windows in CD pa-
tients (Segal and Loewi, 1976), a finding 
that was confirmed and extended to the 
gut in 2006 (Marks et al., 2006). As CD 
is an inflammatory disease, it was hard 
to imagine a more paradoxical and pro-
vocative finding than impaired inflam-
mation  (Korzenik,  2007).  Moreover, 
although CD is principally localized to 
the gut, these studies claimed that the 
inflammatory defect was systemic and 
affected various tissues, such as the skin, 
that were not affected clinically. How-
ever,  as  the  Hungarian  physiologist 
Albert  Szent-Györgyi  pointed  out,   
“a discovery is a discovery because it is 
at variance with accepted knowledge.”
A discovery should also provide an 
explanation for the phenomenon stud-
ied. In a clinical investigation reported 
by Smith et al. (2009) in this issue, Se-
gal’s group studied inflammation in re-
sponse to skin wounded with heat-killed 
bacteria.  Consistent  with  their  past 
studies, patients with CD had impaired 
inflammation  at  the  wound  site,  as 
demonstrated by tracking intravenously 
injected,  radio-labeled  granulocytes. 
Clearance of Escherichia coli at the sites 
of  injection  was  also  impaired  in  pa-
tients with CD, but not in those with 
another inflammatory disease, ulcerative 
colitis, or in healthy subjects. Notably, 
loci.  Moreover,  these  loci  were  not 
found in GWA studies, which instead 
identified yet another set of loci. Alto-
gether, up to 32 CD candidate loci have 
been  identified  by  GWA  studies  and 
replicated  in  at  least  two  population 
samples (Barrett et al., 2008). However, 
for none of these loci do we have a fine 
characterization of the immunological 
impact of the CD-predisposing alleles. 
NOD2 provides us with a preview of 
how  long  and  arduous  a  path  this  is 
likely to be (Noguchi et al., 2009).
Missing heritability and missing 
intelligibility
Paradoxically, experimental difficulties 
in studying CD-associated alleles may 
not be the most challenging roadblock 
ahead. A more difficult issue is that the 
myriad of identified loci do not account 
for the heritability of CD, a problem 
referred to as missing heritability (Maher, 
2008).  Even  given  the  unproven  as-
sumptions that these loci are individu-
ally causal and collectively additive, the 
relative risk conferred by each locus is 
very small, and their overall contribu-
tion  would  account  for  only  20%  of 
CD  heritability.  Even  for  the  three 
main  CD-associated  NOD2  variants, 
the penetrance—or the proportion of 
homozygotes/compound heterozygotes 
who develop disease—is <2%. And out 
of 1,000 CD patients, the number of 
homozygotes/compound heterozygotes 
and heterozygotes is relatively low, at 
an estimated 80 and 270, respectively, 
as compared with 6 and 145 in a healthy 
population (Hugot et al., 2007). More-
over, NOD2 was found to have no role 
in  some  populations  in  which  CD  is 
endemic, such as the Japanese.
An equally important problem with 
these genetic data is that they do not 
add up to a unified or plausible immuno-
logical scenario for the pathogenesis of 
CD. It is difficult to make immuno-
logical sense of these multiple loci and 
pathways, at either the cellular or the 
molecular level. In addition to missing 
heritability,  and  perhaps  even  more 
troubling, is the problem of missing in-
telligibility. Why would CD, which is 
epidemiologically, clinically, and patho-
logically definable, not obey some un-JEM VOL. 206, August 31, 2009 1841
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testinal tract is huge when compared 
with other locations, such as the skin 
or the respiratory, urinary, or genital 
tracts. In fact, the immunodeficiency 
might explain the apparently high rate 
of  appendicitis  in  patients  with  CD 
(Fujita, 2009). Moreover, although the 
gut  is  the  primary  target  of  disease, 
immunodeficiency in patients with CD 
is  not  strictly  limited  to  the  gastro-
intestinal tract, as patients appear to be 
somewhat  more  prone  to  infectious 
diseases elsewhere (e.g., urinary tract 
infections;  Kyle,  1980).  A  systemic 
macrophage  defect  is  also  consistent 
with the occurrence of extraintestinal 
manifestations of CD (Ephgrave, 2007).
If  CD  is  a  phagocyte  immuno-
deficiency  that  combines  a  primary 
macrophage  defect  and  a  secondary 
granulocytic  defect,  one  might  ex-
pect CD to occur in patients with well-
known phagocyte disorders. Indeed, CD 
is known to occur frequently in patients   
with  chronic  granulomatous  disease 
(CGD), which is caused by a group of 
genetically determined defects of the 
phagocyte respiratory burst (Marks et al., 
2009). Patients with CGD often pres-
ent with an intestinal disease indistin-
guishable from CD. Other phagocyte 
primary immunodeficiencies (PID) also 
cause CD in some patients (Rahman 
et al., 2008). Interestingly, however, 
other phagocytic disorders, such as those 
caused by IRAK-4 and MyD88 defi-
ciency, do not seem to predispose to 
CD (Ku et al., 2007; von Bernuth et al., 
2008). Although patients with the latter 
defects are too young and too few for 
researchers  to  draw  firm  conclusions, 
this observation suggests that the CD-
causing macrophage phenotype and the 
resulting  immunodeficiency  may  be 
TLR- and IL-1R–independent.
Could CD be Mendelian?
The fact that CD patients display a mac-
rophage immunodeficiency in turn begs 
the  question  whether  the  macrophage 
defect is truly a genetically determined, 
CD-causing  phenotype.  Ironically,  we 
learned from GWL and GWA studies 
that the genetic architecture of CD may 
not  be  purely  polygenic.  With  up  to 
30% familial forms and a prevalence of 
of bacteria and debris, leading to a T 
cell–mediated granulomatous response.
CD: a macrophage immunodeficiency?
The  macrophage  immunodeficiency 
theory of CD raises at least two questions. 
First, if the macrophage phenotype is 
systemic,  why  does  CD  principally 
occur in the gut? As suggested by the 
bacterial  load–dependent  clearance 
defect, the anatomical selectivity of dis-
ease may reflect the uniquely high bac-
terial load in the intestinal lumen, which 
is  not  found  at  any  other  interface. 
The bacterial content in the gastroin-
the cell. Treatment with lysosomal in-
hibitors restored cytokine production, 
suggesting that some normally secreted 
proteins were erroneously targeted to 
the lysosomes. In conclusion, these stud-
ies provide a plausible, unified explana-
tion for the cellular pathogenesis of CD. 
This  groundbreaking  theory  proposes 
that resident gut macrophages in CD 
patients display a phenotype marked by 
enhanced destruction of cytokines, which 
results in insufficient ignition of inflam-
mation upon mucosal invasion by the 
luminal content. In turn, insufficient in-
flammation results in impaired clearance 
Figure 1.  A model of intestinal chronic inflammation caused by inborn errors of macro-
phages in patients with CD. Macrophages from the patients are intrinsically defective, with im-
paired secretion of cytokines that are normally translated but internally degraded. Because of 
insufficient production of cytokines and chemokines, there is impaired attraction of granulocytes to 
mucosal breaches. Impaired acute, granulocytic inflammation results in impaired clearance of bacte-
ria and debris from the gut wall, itself resulting in chronic, granulomatous inflammation.1842 CROHN’S MACROPHAGES | Casanova and Abel
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cellular phenotype, both to select candi-
date genes expressed in macrophages and 
to test in macrophages the genes found 
by GW approaches in selected multiplex 
or consanguineous families. Regardless 
of the proportion of Mendelian forms of 
CD, and regardless of whatever genetic 
architecture of CD is revealed by com-
prehensive genetic studies, the macro-
phage theory and the known heritability 
of CD together provide a sufficient justi-
fication for referring to CD as a PID of 
macrophages.
This classification further expands the 
field of PID beyond its traditional and 
admittedly  somewhat  arbitrary  pheno-
typic  boundaries  (Casanova  and  Abel, 
2007). CD may actually turn out to be a 
typical PID, affecting patients whose host 
defense is unable to control their com-
mensal,  intestinal  microbial  flora.  This 
scenario is reminiscent of the recent de-
scription of pulmonary alveolar proteinosis   
(PAP) in patients with granulocyte mono-
cyte colony stimulating factor receptor 
mutations (Martinez-Moczygemba et al., 
2008; Suzuki et al., 2008). In these pa-
tients, impaired surfactant destruction by 
alveolar macrophages results in a selective 
pulmonary phenotype, although the de-
fect is shared by macrophages present in 
all tissues. There is a striking resem-
blance between CD and PAP, as both 
conditions are organ-specific manifesta-
tions  of  an  inherited,  systemic  macro-
phage  deficiency.  The  pivotal  role  of 
macrophages  in  multiple  physiological 
processes and the diverse phenotypes re-
lated to macrophage defects found in the 
mouse model (Vidal et al., 2008) suggest 
that other human diseases, besides CD 
and PAP, may eventually turn out to be 
the result of macrophage anomalies. PIDs 
indiscriminately affecting various types 
of phagocytes have long been collected. 
The  hunt  for  macrophage  PIDs  has 
just begun.
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